We recently compiled a list of the 10 Best European Dividend Stocks To Buy. In this article, we are going to take a look at ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

In the current session, Sanofi Inc. SNY -0.18% + Free Alerts is trading at $48.30, after a 0.18% decrease. Over the past ...

Sanofi SNY and its partner SK bioscience announced that they have expanded their agreement to develop, license and ...

Sanofi is handing SK bioscience 50 million euros ($52 million) as the longtime partners take their next-gen pneumococcal ...

Sanofi has announced the appointment of Jean-Paul Kress as an independent director to its Board, effective January 1, 2025. Kress, with over 30 years of experience in the pharmaceutical industry, ...

The 340B program has become a flash point in the growing debate over the cost of prescription drugs in the U.S.

▎药明康德内容团队编辑赛诺菲（Sanofi）公司今日宣布，美国FDA已授予在研布鲁顿氏酪氨酸激酶（BTK）抑制剂tolebrutinib突破性疗法认定，用于治疗患有非复发性继发进展型多发性硬化（nrSPMS）的成年患者。突破性疗法认定旨在加速针对严重或危及生命疾病的药物的开发与审评。获得该认定的药物需显示出初步临床证据，证明其在 ...

Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Sanofi (SNYNF, SNY) and SK bioscience have entered an expanded agreement to develop, license and commercialize next-generation ...

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...